Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (760)	12/20/2007 12:37:02 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

INGN's stock shows no sign of trying to close today's DG.<g> bigcharts.marketwatch.com The AP came out with the same "news" about Advexin's PIII plans for "extended data" on the patient's p53 biomarkers.On the last paragraph it mentions that a midstage study of the drug showed it shrunk tumors in 40% of head and neck cancer patients. biz.yahoo.com But the AP note doesn't mention that the patients that showed positive results also showed a positive correlation with the p53 marker, as was displayed at the AACR meeting & posted here by Elizabeth back in March. Message 23371275 Samples were available from 28 patients with recurrent SCCHN who were subsequently treated with Advexin in Phase II clinical trials. p53 protein overexpression (>20% positive cells) had a statistically significant correlation with locoregional tumor disease control (CR, PR, or SD, all of >3 months duration) and increased median survival following Advexin treatment. 75% (12/16) of patients with p53+ tumors demonstrated locoregional disease control, compared to only 18% (2/11) of patients with p53- tumors (p=0.0063; Fisher’s Exact Test). In addition, the median survival of patients with tumors overexpressing p53 protein (p53+) was 11.6 months, compared to only 3.5 months in patients whose tumors were p53- (p=0.0007; Log-Rank Test). In conclusion, analysis of pre-treatment tumor samples has revealed that overexpression of p53 protein is a predictive biomarker that identifies a subset of patients most likely to benefit from p53 gene therapy, as indicated both by increased tumor response and survival. The subpopulation of patients identified by this biomarker is known to have a poor prognosis and is generally the most resistant to conventional treatments. Our findings indicate that p53 overexpression identifies a population of patients with defective apoptotic pathways that can benefit from treatment with the normal p53 gene. Snip As I mentioned, it seems that it is too soon to make any definite conclusions about Advexin, although I still like more the INGN-241 <g> Bernard P.S. There were some Upticks as I was writing this note & the stock bounced a little from its 3.05 low to 3.20 at present.(None of those upticks of 10Ks & 14Ks were mine.<g>)